1. Home
  2. TOUR vs ACRS Comparison

TOUR vs ACRS Comparison

Compare TOUR & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tuniu Corporation

TOUR

Tuniu Corporation

HOLD

Current Price

$0.72

Market Cap

87.0M

ML Signal

HOLD

Logo Aclaris Therapeutics Inc.

ACRS

Aclaris Therapeutics Inc.

HOLD

Current Price

$2.67

Market Cap

314.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TOUR
ACRS
Founded
2006
2012
Country
China
United States
Employees
N/A
N/A
Industry
Transportation Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
87.0M
314.2M
IPO Year
2014
2015

Fundamental Metrics

Financial Performance
Metric
TOUR
ACRS
Price
$0.72
$2.67
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$9.75
AVG Volume (30 Days)
225.1K
1.2M
Earning Date
12-05-2025
02-26-2026
Dividend Yield
5.14%
N/A
EPS Growth
N/A
N/A
EPS
0.01
N/A
Revenue
$78,261,883.00
$15,742,000.00
Revenue This Year
$12.27
N/A
Revenue Next Year
$10.18
N/A
P/E Ratio
$107.12
N/A
Revenue Growth
9.07
N/A
52 Week Low
$0.62
$1.05
52 Week High
$1.17
$3.48

Technical Indicators

Market Signals
Indicator
TOUR
ACRS
Relative Strength Index (RSI) 50.07 42.35
Support Level $0.62 $2.49
Resistance Level $0.74 $3.04
Average True Range (ATR) 0.05 0.18
MACD 0.01 -0.07
Stochastic Oscillator 71.86 24.68

Price Performance

Historical Comparison
TOUR
ACRS

About TOUR Tuniu Corporation

Tuniu Corp is an online leisure travel company. The company is engaged in the provision of travel-related services in the People's Republic of China. It offers a large selection of packaged tours, including organized tours and self-guided tours, as well as travel-related services for leisure travelers. The company's organized tours provide pre-arranged itineraries, transportation, accommodations, entertainment, meals, and tour guide services. Its self-guided tours consist of combinations of flights and hotel bookings and other optional add-ons. The company derives almost all of its revenue from PRC.

About ACRS Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.

Share on Social Networks: